Prostate cancer patients carrying genetic abnormalities -- deletion of the PTEN gene as well as ERG or ETV1 gene rearrangement -- had lower chances of survival than those who had none of the gene mutations, U.K. scientists found. "Men diagnosed with prostate cancer could be tested for all three genetic alterations, and this information could be used to help determine how aggressively they should be treated," the study's lead researcher said.

Full Story:

Related Summaries